{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:08Z","timestamp":1787988008065,"version":"build-2784847793"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00259-026-07962-8","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:15:29Z","timestamp":1780470929000},"page":"6605-6609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interpreting [18F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET\/CT sub-study of the Phase 3 GMMG-HD7 trial"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-8741","authenticated-orcid":false,"given":"Christos","family":"Sachpekidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Hajiyianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wennmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Kopp-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Dapunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Menis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Brobeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias K.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"7962_CR1","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206\u201317.","journal-title":"Lancet Oncol"},{"key":"7962_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.20.00386","volume":"39","author":"E Zamagni","year":"2021","unstructured":"Zamagni E, Nanni C, Dozza L, et al. Standardization of 18F-FDG-PET\/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2021;39:116\u201325.","journal-title":"J Clin Oncol"},{"key":"7962_CR3","doi-asserted-by":"publisher","first-page":"6252","DOI":"10.1182\/bloodadvances.2024015686","volume":"9","author":"E Zamagni","year":"2025","unstructured":"Zamagni E, Talarico M. Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going. Blood Adv. 2025;9:6252\u201366.","journal-title":"Blood Adv"},{"key":"7962_CR4","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/leu.2010.62","volume":"24","author":"E Terpos","year":"2010","unstructured":"Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia. 2010;24:1043\u20139.","journal-title":"Leukemia"},{"key":"7962_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19:370\u201381.","journal-title":"Lancet Oncol"},{"issue":"5","key":"7962_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"key":"7962_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00259-024-06858-9","volume":"52","author":"C Nanni","year":"2024","unstructured":"Nanni C, Deroose CM, Balogova S, et al. EANM guidelines on the use of [18F]FDG PET\/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders. Eur J Nucl Med Mol Imaging. 2024;52:171\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7962_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","volume":"43","author":"C Nanni","year":"2016","unstructured":"Nanni C, Zamagni E, Versari A, et al. Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43:414\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7962_CR9","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, et al. German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9:e810\u201321.","journal-title":"Lancet Haematol"},{"key":"7962_CR10","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1200\/JCO-24-02266","volume":"43","author":"EK Mai","year":"2025","unstructured":"Mai EK, Bertsch U, Pozek E, et al. German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators; German-speaking Myeloma Multicenter Group (GMMG) HD7. Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. J Clin Oncol. 2025;43:1279\u201388.","journal-title":"J Clin Oncol"},{"key":"7962_CR11","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00259-025-07599-z","volume":"53","author":"C Sachpekidis","year":"2026","unstructured":"Sachpekidis C, Hajiyianni M, Gr\u00f6zinger M, et al. Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET\/CT sub-study of the Phase 3 GMMG-HD7 Trial. Eur J Nucl Med Mol Imaging. 2026;53:1509\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7962_CR12","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068\u201376.","journal-title":"Blood"},{"key":"7962_CR13","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989\u201395. Erratum in: Blood. 2012; 120:2349.","journal-title":"Blood"},{"key":"7962_CR14","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, et al. Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM\/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017;35:2911\u20138.","journal-title":"J Clin Oncol"},{"key":"7962_CR15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","volume":"103","author":"FE Davies","year":"2018","unstructured":"Davies FE, Rosenthal A, Rasche L, et al. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018;103:1047\u201353.","journal-title":"Haematologica"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07962-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07962-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07962-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:34Z","timestamp":1787986834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07962-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7962"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07962-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants enrolled in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent to publish has been received from all participants.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no competing financial interests in relation to the work described. Christos Sachpekidis is an associate editor in this journal. Hartmut Goldschmidt declares the following: Grants and\/or provision of Investigational Medicinal Product: Amgen, Array Biopharma\/Pfizer, BMS\/Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Mundipharma GmbH, Sanofi. Research Support: Amgen, BMS, Celgene, GlycoMimetics Inc., GSK, Heidelberg Pharma, Hoffmann-La Roche, Karyopharm, Janssen, Incyte Corporation, Millenium Pharmaceuticals Inc., Molecular Partners, Merck Sharp and Dohme (MSD), MorphoSys AG, Pfizer, Sanofi, Takeda, Novartis. Advisory Boards: Adaptive Biotechnology, Amgen, BMS, Janssen, Sanofi, Honoraria \/ Nebent\u00e4tigkeiten: Amgen, BMS, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer. Support for attending meetings and\/or travel: Amgen, BMS, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer. Elias K. Mai reports the following: Consulting or advisory role: Amgen, Bristol Myers Squibb\/BMS, GlaxoSmithKline\/GSK, Janssen-Cilag\/J&J, Oncopeptides, Pfizer, Sanofi, Stemline and Takeda. Honoraria: Amgen, Bristol Myers Squibb\/BMS, GlaxoSmithKline\/GSK, Janssen-Cilag\/J&J, Oncopeptides, Pfizer, Sanofi, Stemline and Takeda. Research funding: Bristol Myers Squibb\/BMS, Janssen-Cilag\/J&J, Sanofi and Takeda. Travel accommodations and expenses: Bristol Myers Squibb\/BMS, GlaxoSmithKline\/GSK, Janssen-Cilag\/J&J, Pfizer, Sanofi, Stemline and Takeda. All other authors declare no conflicts of interest.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}